| Course | HCR 576 Drug Discovery, Development and Regulations |
|---|---|
| Module | Module 1 |
| Paper type | Target product profile |
| Length | About 643 words, 5 pages |
| Format | APA 7 student paper |
| School | Arizona State University |
| Program | MS in Regulatory Science |
| Updated | October 2026 |
Free sample paper for HCR 576 Module 1
Target Product Profile: A Once-Daily Aldosterone Synthase Inhibitor for Treatment-Resistant Hypertension
Student Name
MS in Regulatory Science, Arizona State University
HCR 576: Drug Discovery, Development and Regulations
Instructor Name
Month Day, Year
Target Product Profile: A Once-Daily Aldosterone Synthase Inhibitor for Treatment-Resistant Hypertension
Purpose of a Target Product Profile
A target product profile (TPP) summarizes the drug a sponsor intends to bring to market, organized by the sections of its future label. Writing it at the start of development aligns teams and regulators on what the drug must achieve and lets each study be designed to show it. FDA's draft guidance describes the profile as a strategic tool organized by the sections of the label (U.S. Food and Drug Administration, 2007), and the ICH Q8 guideline, which FDA adopted, calls a similar summary for manufacturing the quality target product profile (U.S. Food and Drug Administration, 2009). This profile covers drug ABX-210, a hypothetical oral aldosterone synthase inhibitor.
The Drug and the Need
Hypertension counts as resistant when pressure stays above target even though the patient takes three drugs from different classes, one of them a diuretic. Excess aldosterone contributes to many cases, but mineralocorticoid receptor blockers such as spironolactone cause hyperkalemia and, in men, breast enlargement. Inhibiting the enzyme that makes aldosterone is a newer approach. In a Phase 2 trial of baxdrostat, a drug in this class, the 2-mg dose lowered systolic blood pressure by 11.0 mm Hg more than placebo after 12 weeks in patients on at least three antihypertensives, with no adrenal insufficiency and two patients with potassium of 6.0 mmol/L or higher (Freeman et al., 2023). Those results set realistic benchmarks for ABX-210.
The Profile
| Attribute | Minimum acceptable | Ideal target |
|---|---|---|
| Indication | Add-on treatment of hypertension not controlled on three or more agents including a diuretic | Same, plus primary aldosteronism not suitable for surgery |
| Population | Adults 18 and older, eGFR 45 mL/min/1.73 m2 or higher | Adults including eGFR 30 or higher |
| Dosage form and regimen | Oral tablet once daily | Once daily, no titration, with or without food |
| Primary efficacy endpoint | Placebo-adjusted reduction in seated systolic blood pressure of at least 8 mm Hg at 12 weeks | At least 11 mm Hg |
| Secondary efficacy | Reduction in 24-hour ambulatory systolic pressure; proportion reaching goal | Durable effect to 52 weeks |
| Key safety | Serum potassium above 6.0 mmol/L in under 2% of patients; no adrenal insufficiency | Under 1%; no monitoring beyond standard potassium checks |
| Tolerability | Discontinuation for adverse events no higher than placebo plus 3% | Equal to placebo |
| Drug interactions | Manageable with labeled dose adjustments | No clinically important CYP interactions |
| Storage | Room temperature, 24-month shelf life | 36 months |
| Outcomes (postapproval) | None required at approval | Cardiovascular outcomes trial showing fewer events |
Endpoint Characteristics
The primary endpoint, change in seated office systolic blood pressure from baseline to week 12 compared with placebo, is an established surrogate endpoint for antihypertensive approval because lowering blood pressure reliably reduces stroke and heart attack. To limit measurement error, readings will be taken by automated devices in triplicate after five minutes of rest. Twenty-four-hour ambulatory blood pressure, a secondary endpoint, rules out white-coat effects and shows coverage across the dosing interval, which matters for a once-daily drug. The key safety endpoint, serum potassium, reflects the class's main risk, and cortisol testing will confirm that the drug does not suppress the adrenal hormones it is meant to spare.
How the Profile Guides Development
The minimum targets define a go or no-go decision at the end of Phase 2: if ABX-210 cannot reach an 8 mm Hg placebo-adjusted reduction with acceptable potassium safety, it will not advance. The ideal targets guide Phase 3 design, such as including patients with lower kidney function and adding a 52-week extension. The profile will be shared with the FDA at the end-of-Phase 2 meeting and updated as data accumulate.
Conclusion
A target product profile turns a drug concept into measurable commitments. For ABX-210, the profile defines what success looks like on efficacy, safety and convenience, ties each commitment to an endpoint and sets the evidence bar for continuing development.
References
Freeman, M. W., Halvorsen, Y.-D., Marshall, W., Pater, M., Isaacsohn, J., Pearce, C., Murphy, B., Alp, N., Srivastava, A., Bhatt, D. L., & Brown, M. J. (2023). Phase 2 trial of baxdrostat for treatment-resistant hypertension. New England Journal of Medicine, 388(5), 395-405. https://doi.org/10.1056/NEJMoa2213169
U.S. Food and Drug Administration. (2007). Guidance for industry and review staff: Target product profile, a strategic development process tool [Draft guidance]. https://www.fda.gov/media/72566/download
U.S. Food and Drug Administration. (2009). Q8(R2) pharmaceutical development [Guidance for industry]. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/q8r2-pharmaceutical-development
What the HCR 576 Module 1 instructions ask for
HCR 576 begins with drug discovery and the approval process, and its first paper, due in Week 1, uses the course's Product Profile Template. The syllabus states the purpose plainly: understand the characteristics of a drug under development and establish the endpoint characteristics of a drug. In industry this document is a target product profile, a summary of the label a sponsor hopes to earn, with minimum acceptable and ideal targets for each attribute. Week 1 readings include Mathieu's New Drug Development: A Regulatory Overview and ICH Q8, which introduces the quality target product profile for manufacturing. Choose a drug concept with a clear unmet need and a class or comparator you can benchmark against, so your targets are grounded in evidence, and explain how each endpoint will be measured, since endpoint characteristics are the second half of the prompt.
How the HCR 576 Module 1 example is put together
The sample opens by explaining what a target product profile is and why sponsors write one, citing the ICH guideline the course assigns. A section on the drug and the unmet need introduces the class and reports benchmark results from a published Phase 2 trial. The profile itself is a ten-row table with minimum and ideal targets for indication, population, dosing, efficacy, safety, tolerability, interactions, storage and outcomes. An endpoint section explains how the primary, secondary and safety endpoints will be measured and why each is appropriate. A short section shows how the profile drives go or no-go decisions, and the conclusion restates its purpose.
Reading the HCR 576 Module 1 grading rubric
The product profile paper is one of three papers that together count for 22.5% of the HCR 576 grade. Credit goes to a drug concept with a clear rationale, a profile organized by label attributes with both minimum and ideal targets, targets grounded in published evidence or regulatory precedent, endpoints that are appropriate for the indication and clearly defined and an explanation of how the profile guides development. Points are lost when targets are vague ("well tolerated"), when endpoints are named without saying how they are measured, when the profile ignores the drug's main safety risk and when the concept is not realistic. Readers in a regulatory program also value awareness of surrogate endpoints and of what the FDA accepts for the indication.
HCR 576 Module 1 help from the desk
Pick a drug class with published trials so you can benchmark. Organize the profile by label sections and give each a minimum and an ideal target. Make efficacy and safety targets numeric. Define the primary endpoint precisely: measure, time point and comparison. Address the class's main safety concern directly. Explain one decision the profile would drive. If you want a check that your targets are realistic, the desk can compare them with published trials in your class. Keep the profile to one table and a few pages; a profile is a summary, so length is not a virtue. Revisit it when your later papers in the course add facts, since sponsors update a profile as evidence accumulates.
Write yours, or have the desk draft it
This paper is an original model document written by our desk, not a submitted student paper and not an official Arizona State University document. Read it for the moves, then write your own to the instructions in your classroom. If you want one built to your exact prompt and rubric, the first custom sample is free and arrives in 24 to 48 hours.
More HCR 576 and MS in Regulatory Science sample papers
- HCR 576 Module 5: Paper: A Recent Drug Recall and the FDA Process
- HCR 576 Module 7: Paper: Comparing the U.S. and EU Regulatory Frameworks
- HCR 579 Module 4: Written Assignment 3: Dissecting a Phase 0 Study
- HCR 555 Module 5: Assignment 4: Globalization, Off-Label Use, Biologics and Counterfeits
- HCR 563 Module 5: Assignment 3: Annotated Bibliography on Decentralized Trials
- HCR 543 Module 7: Summative Evaluation Paper: Emerging Food Safety Issues
HCR 576 Module 1 questions, answered
Where can I find a free HCR 576 Module 1 sample paper?
This page has a full HCR 576 product profile sample for a hypothetical aldosterone synthase inhibitor in resistant hypertension.
What is a target product profile?
A summary of the label a sponsor aims to earn, with minimum and ideal targets for indication, efficacy, safety, dosing and other attributes.
What are endpoint characteristics in a product profile?
The definition, measurement method, time point and comparison for each efficacy and safety endpoint the drug must meet.
Why include minimum and ideal targets?
Minimum targets set go or no-go thresholds; ideal targets show the best-case label that guides later studies.
Which textbook does HCR 576 use?
Mathieu's New Drug Development: A Regulatory Overview.